|Synonyms||Fladrafinil, Fluorafinil, 2-(bis(4-fluorophenyl)methylsulfinyl)-N-hydroxyacetamide|
|Molecular Weight||325.33 g/mol|
|Solubility||Poorly soluble in water; Soluble to 5 mg / mL in ethanol; Soluble to 10 mg / mL in isopropanol|
|Storage Condition||Store at room temperature or cooler, in a sealed airtight container, protected from heat, light and humidity.|
|Application||Fladrafinil is a wakefulness-promoting agent. It was found to produce antiaggressive effects in animals.|
On a chemical level, Fladrafinil is an adrafinil derivative, specifically a bis(p-fluro) ring-substitute. Effects additional to enhanced wakefulness include quickened cogitation. Fladrafinil also boosts neural functioning, increases recollection, and heightens ambition. It achieves these effects by activity related to histamine and dopamine neurotransmitters.
02 Base Information
03 Fladrafinil (90212-80-9) General Description
Another name for Fladrafinil is fluorafinil and its chemical designation is CRL – 40 941. It is classified as an eugeroic and its action promotes wakefulness. It is very similar in its composition and effects to modafinil and adrafinil. However, it also induces an anti-aggressive response whereas these two similar drugs do not.
Fladrafinil is known to have minor to zero side effects, provided the recommended dosage and frequency are adhered to over a limited span of time. This drug should is NOT intended for extended usage.
04 Fladrafinil (CRL-40,941) (90212-80-9) History
In a recent (2017) study, researchers from Ireland studied the thermal degradation properties of several eugeroic agents including Modafinil, Adrafinil, CRL-40,940, and CRL-40,941. Their study produced interesting findings relating to the results of thermal degradation of Nootropics. They “identified a common GC injector port thermolysis product in the analysis of modafinil, adrafinil and modafinic acid” and proposed a mechanism for its formation. Furthermore, they found that CRL-40,940, CRL-40,941 and modafiendz produced the same degradant profile – which could lead to difficulties during forensic analysis.
05 Fladrafinil (90212-80-9) Mechanism Of Action
CRL 40941 has neuropsychopharmacological properties similar to those of adrafinil which is a known psychotonic agent.
It differs from the latter by its anti-aggressive properties and its action with respect to electric shock.
It has been observed that CRL 40941 presents another advantage over CRL 40028 [adrafinil] regarding assimilation by the oral route; in fact, CRL 40941, as psychotonic agent, is clearly more effective by the oral route, in the rat and in man, than CRL 40028.
From the clinical point of view, CRL 40941 acts at doses which are half those of CRL 40028.
Excellent results were obtained in man when it was administered per os, at the rate of 2 to 3 capsules or tablets (each containing 50 mg of active ingredient) per day, particularly for 2 to 8 weeks in the treatment of hypersomnia and psychasthenia.
06 Fladrafinil (CRL-40,941) (90212-80-9) Application
CRL-40,941 (Item No. 19138) is an analytical reference standard categorized as a nootropic. This product is intended for research and forensic applications.
CRL-40,941 (Fladrafinil) is a psychotonic and eurgeroic (wakefulness-promoting substance) that is related to Adrafinil and CRL-40,940, with similar but more potent effects demonstrated in animal models. Fladrafinil is the bis(p-fluoro) derivative of Adrafinil, and is, therefore, often referred to as “Fladrafinil”. Unfortunately, very little literature currently exists for this compound.Unlike its parent compound, CRL-40, 941 also appears to demonstrate some interesting anti-aggressive (calming) properties in animal studies – according to the original 1983 patent filed by the Parisian Laboratoire
07 Fladrafinil (CRL-40,941) More research
The research team at Laboratoire Lafon observed that CRL-40,941 had similar psychotonic and eurgeroic properties as Adrafinil – albeit with improved bioavailability through oral administration. The unique characteristic of CRL-40,941 is its anti-aggressive properties in animal models, which sets it apart from both Modafinil and Adrafinil.
An excerpt from the original CRL-40,941 patent states that:
“CRL 40,941,as a psychotonic agent, is clearly more effective by the oral route, in the rat and in man, than [Adrafinil]. From the clinical point of view, CRL 40,941 acts at doses which are half those of [Adrafinil]. Excellent results were obtained in man when [CRL 40,941] was administered per os, at the rate of 2 to 3 capsules or tablets, (each containing 50mg of active ingredient) per day, particularly for 2 to 8 weeks in the treatment of hypersomnia and psychastenia.”
08 Fladrafinil (90212-80-9) Document Download
09 Fladrafinil (CRL-40,941) (90212-80-9) Reference
- Dowling, G., Kavanagh, P.V., Talbot, B., et al. Outsmarted by nootropics? An investigation into the thermal degradation of modafinil, modafinic acid, adrafinil, CRL-40,940 and CRL-40,941 in the GC injector: formation of 1,1,2,2-tetraphenylethane and its tetra fluoro analog Drug Test Anal. 9(3), 518-528 (2017).
- 01. Overview
- 02. Base Information
- 03. Fladrafinil (90212-80-9) General Description
- 04. Fladrafinil (CRL-40,941) (90212-80-9) History
- 05. Fladrafinil (90212-80-9) Mechanism Of Action
- 06. Fladrafinil (CRL-40,941) (90212-80-9) Application
- 07. Fladrafinil (CRL-40,941) More research
- 08. Fladrafinil (90212-80-9) Document Download
- 09. Fladrafinil (CRL-40,941) (90212-80-9) Reference